Drug Name: Columvi

Indications: To treat diffuse large B-cell lymphoma, not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma after two or more lines of systemic therapy.

Active Ingredient: Glofitamab-gxbm

Company: Genentech, Inc

Approval Date: 6/15/2023

More Details: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761309s000lbl.pdf

Leave a Reply

Your email address will not be published. Required fields are marked *